Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: tofacitinib
Biological: adalimumab
Biological: etanercept

Registration Number: NCT02092467

Lead Sponsor: Pfizer

Brief Summary: This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 4372

Inclusion Criteria

Moderate to severe rheumatoid arthritis
Taking methotrexate without adequate control of symptoms
Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)

Exclusion Criteria

Current or recent infection
Clinically significant laboratory abnormalities
Pregnancy

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment Arm 1	tofacitinib	-
Treatment Arm 2	tofacitinib	-
Treatment Arm 3	adalimumab	TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
Treatment Arm 3	etanercept	TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.

Primary Outcome Measures

Name	Time	Method
Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)	Baseline up to last contact date (maximum up to 72 months)	Incidence rate (number of participants with event per 100 participant year \[PY\]) was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Malignancy events, excluding NMSC were adjudicated by a steering committee. The risk period (RP) was the last contact date. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)	Baseline up to last contact date (maximum up to 72 months)	MACE included the cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke of any classification, including reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With an American College of Rheumatology 50% (ACR50) Response	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	ACR50 response is a \>= 50% improvement in TJC (28) and SJC (28) and \>=50% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
Number of Participants With an American College of Rheumatology 70% (ACR70) Response	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	ACR70 response is a \>= 70% improvement in TJC (28) and SJC (28) and \>=70% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
Percentage of Participants With Simplified Disease Activity Index (SDAI) Less Than or Equal to (<=) 3.3	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
Incidence Rate of Non-fatal Stroke	Baseline up to last contact date (maximum up to 72 months)	Non-fatal stroke included reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Incidence Rate of Non-fatal Myocardial Infarction	Baseline up to last contact date (maximum up to 72 months)	Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Incidence Rate of Adjudicated Opportunistic Infection Events Including Tuberculosis	Baseline up to last contact date (maximum up to 72 months)	Opportunistic infections (OI) were reviewed and adjudicated by the opportunistic infection review committee (OIRC). Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Incidence Rate of Adjudicated Hepatic Events	Baseline up to last contact date (maximum up to 72 months)	Hepatic events (adjudicated) included drug-induced liver injury (DILI) - probable, highly likely and definite, DILI - listed separately, DILI - cases meeting classification and severity, participants with elevations of transaminase levels greater than (\>) 1\* upper limit of normal (ULN), greater than or equal to (\>=) 3\ULN, \>=5\ULN (based on laboratory values). Incidence rate was the total number of participants with admissible events divided by total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was minimum of The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.
Number of Participants With Reasons For Permanent or Temporary Discontinuation of Study Medication	Baseline up to last contact date (maximum up to 72 months)	Number of participants who permanent or temporary discontinued study medication due to any AE, treatment related AEs, Coronavirus disease 2019 (COVID 19) related AEs, and herpes zoster were reported. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (milligrams per liter \[mg/L\]) and patient's global assessment of disease activity (PtGA) on a 100 mm Visual Analog Scale (VAS) (scores ranging from 0 millimeter \[mm\] \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\sqrt(TJC28) + 0.28\sqrt(SJC28) + 0.36\ln(CRP in mg/L +1) + 0.014\PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root.
Incidence Rate of Adjudicated Cardiovascular Events Other Than Major Adverse Cardiovascular Events (MACE)	Baseline up to last contact date (maximum up to 72 months)	Cardiovascular events (adjudicated) were death (coronary and non-coronary), MI, all coronary revascularization, unstable angina, new ischemic heart disease, stroke (fatal and non-fatal), transient ischemic attack (TIA), congestive heart failure (CHF), peripheral arterial vascular disease (PAVD), deep vein thrombosis, pulmonary embolism, arterial embolism, arterial thrombosis. Incidence rate was total number of participants with admissible events divided by total (for all qualifying participants) time at risk for cohort/treatment group of interest. Risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs: Baseline up to minimum of last contact date or last study treatment dose date+28 days (maximum up to 72 months); SAEs: Baseline up to minimum of last contact date (maximum up to 72 months)	AE was any untoward medical occurrence post treatment; event need not necessarily had causal relationship with treatment or usage. SAE: any untoward medical occurrence at any dose: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly. TEAE: event that occurred for first time during effective duration of treatment and not seen prior to start of treatment or event seen prior to start of treatment but increase in severity during treatment. Risk period (RP) for AE: minimum of last contact date or last study treatment dose date+28 days. RP for SAEs: last contact date. Last contact date was maximum: AE start, AE stop, last study visit, withdrawal and telephone contact. In case of death, last contact was death date. First events counted within RP. Participant did not have event or had event outside risk period were censored at end of RP.
Number of Participants With Clinically Significant Abnormal Laboratory Parameters	Baseline up to last contact date (maximum up to 72 months)	Clinically significant laboratory abnormalities: Hematology: hemoglobin, hematocrit, erythrocytes with primary criteria as less than \[\<\] 0.8\* lower limit of normal \[LLN\]), platelets (\<0.5\* LLN; \>1.75\* ULN), leukocytes (\<0.6\LLN; \>1.5\ULN), lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes (\<0.8\LLN; \>1.2\ULN), eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes (\>1.2\ULN); urinalysis: urine glucose, urine protein, urine hemoglobin, and leukocyte esterase (\>=1); chemistry: bilirubin, indirect bilirubin (\>1.5\ULN) aspartate aminotransferase, alanine aminotransferase (\>3.0\ULN), creatinine, triglycerides, cholesterol (\>1.3\ULN) and HDL cholesterol (\<0.8\*LLN). Risk period (RP) was minimum of last contact date or last study treatment dose date+28 days. Last contact date was (date of death or maximum of dates: AE start, AE stop, last study visit, withdrawal, telephone contact). Participants without event or event outside RP were censored at end of RP.
Incidence Rate of Adjudicated All-Cause Deaths	Baseline up to last contact date (maximum up to 72 months)	All-cause death was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths (adjudicated by Adjudication Committee) was reported in this outcome measure. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
Change From Baseline in Simplified Disease Activity Index (SDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and physician's global assessment of health (PhyGA) both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63	CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
Percentage of Participants Who Achieved Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	ACR-EULAR Boolean-based definition of remission participant must satisfy all of the following: TJC28 \<=1, SJC28 \<=1, CRP \<=10 mg/L, PtGA on a 0-100 mm scale, higher scores indicate greater affection due to disease activity.
Percentage of Participants With Clinical Disease Activity Index (CDAI) <=2.8	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
Percentage of Participants With Simplified Disease Activity Index (SDAI) <=11	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.
Percentage of Participants With Clinical Disease Activity Index (CDAI) <=10	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.
Percentage of Participants With Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) <=3.2	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\sqrt(TJC28) + 0.28\sqrt(SJC28) + 0.36\ln(CRP in mg/L +1) + 0.014\PtGA in mm+ 0.96.
Number of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response	Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72	ACR20 response is a \>= 20% improvement in TJC (28) and SJC (28) and \>=20% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.

Trial Locations

Locations (339): Arthritis and Rheumatology of GA, P.C.
🇺🇸
Atlanta, Georgia, United States
Baylor Scott and White Research Institute / Arthritis Care and Research Center
🇺🇸
Dallas, Texas, United States
UPMC Arthritis and Autoimmunity Clinic
🇺🇸
Pittsburgh, Pennsylvania, United States
The Center for Rheumatology and Bone Research, a division of Arthritis and Rheumatism Associates, PC
🇺🇸
Wheaton, Maryland, United States
Accurate Clinical Management, LLC
🇺🇸
Houston, Texas, United States
Rheumatic Disease Clinical Research Center
🇺🇸
Houston, Texas, United States
Houston Institute for Clinical Research
🇺🇸
Houston, Texas, United States
Medical Center Research, LLC
🇺🇸
Houston, Texas, United States
Centro de Investigacion en Salud - Centro de Excelencia en Reumatologia
🇵🇪
Lima, Peru
Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka Partnerska
🇵🇱
Elblag, Poland
Centrum Medyczne Pratia Gdynia
🇵🇱
Gdynia, Poland
AAGS, s.r.o., Reumatologicka ambulancia
🇸🇰
Dunajska Streda, Slovakia
Doctors Research Institute
🇺🇸
Miami, Florida, United States
Center for Arthritis and Rheumatic Diseases
🇺🇸
Miami, Florida, United States
San Diego Arthritis Medical Clinic
🇺🇸
San Diego, California, United States
Steinberg Diagnostics
🇺🇸
Las Vegas, Nevada, United States
EKSAKTI, LLC (dba: Eksakti Clinical Research)
🇺🇸
Las Vegas, Nevada, United States
Cincinnati Rheumatic Disease Study Group, Inc.
🇺🇸
Cincinnati, Ohio, United States
Professional Research Network of Kansas, LLC
🇺🇸
Wichita, Kansas, United States
Hospital das Clinicas Universidade Federal de Minas Gerais
🇧🇷
Belo Horizonte, Minas Gerais, Brazil
EmergeOrtho,P.A.
🇺🇸
Durham, North Carolina, United States
Health Research of Oklahoma
🇺🇸
Oklahoma City, Oklahoma, United States
Oklahoma Medical Research Foundation (OMRF)
🇺🇸
Oklahoma City, Oklahoma, United States
Lynn Health Science Institute
🇺🇸
Oklahoma City, Oklahoma, United States
Center For Inflammatory Disease
🇺🇸
Nashville, Tennessee, United States
Pharmacy Department
🇬🇧
Wolverhampton, United Kingdom
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
🇧🇷
São Jose do Rio Preto, SAO Paulo, Brazil
Austin Repatriation Hospital
🇦🇺
Heidelberg, Victoria, Australia
Clinical and Translational Research Center of Alabama, PC
🇺🇸
Tuscaloosa, Alabama, United States
Desert Medical Advances
🇺🇸
Palm Desert, California, United States
Sierra Rheumatology, Inc.
🇺🇸
Roseville, California, United States
RASF-Clinical Research Center, Inc
🇺🇸
Boca Raton, Florida, United States
Coeur D'Alene Arthritis Clinic
🇺🇸
Coeur d'Alene, Idaho, United States
Florida Medical Clinic, P.A.
🇺🇸
Zephyrhills, Florida, United States
MidWest Clinical Research, LLC
🇺🇸
Overland Park, Kansas, United States
Diagnostic Rheumatology and Research PC
🇺🇸
Indianapolis, Indiana, United States
RK Will Pty Ltd
🇦🇺
Victoria Park, Western Australia, Australia
Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno (CEMIC)
🇦🇷
C.a.b.a., Caba, Argentina
Revmatologie, s.r.o.
🇨🇿
Brno, Czechia
The Chaim Sheba Medical Center
🇮🇱
Tel-Hashomer, Israel
UT Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
Artroscan, s.r.o.
🇨🇿
Ostrava, Czechia
Meir Medical Center
🇮🇱
Kfar Saba, Israel
Medicine Professional Corporation
🇨🇦
Ottawa, Ontario, Canada
REVMACLINIC s.r.o.
🇨🇿
Brno, Czechia
Centro Privado de Medicina Familiar - Mindout Research S.R.L.
🇦🇷
Caba, Argentina
Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C
🇲🇽
Culiacan, Sinaloa, Mexico
EDUMED - Educacao em Saude SS Ltda
🇧🇷
Curitiba, PR, Brazil
Hadassah Medical Center - Hebrew University Hospital
🇮🇱
Jerusalem, Israel
Rabin Medical Center
🇮🇱
Petah Tikva, Israel
Ain Wazein Hospital
🇱🇧
Lebanon, Lebanon
UMBAL "Dr Georgi Stranski" EAD
🇧🇬
Pleven, Bulgaria
SER - Servicos Especializados em Reumatologia da Bahia
🇧🇷
Salvador, BA, Brazil
PerCuro Clinical Research Limited
🇨🇦
Victoria, British Columbia, Canada
CEDOES - Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo
🇧🇷
Vitoria, Espírito Santo, Brazil
Tel Aviv Sourasky Medical Center
🇮🇱
Tel Aviv, Israel
Hotel Dieu de France Hospital
🇱🇧
Achrafieh, Beirut, Lebanon
Centre de Rhumatologie de l'Est du Quebec
🇨🇦
Rimouski, Quebec, Canada
Clinical Research and Arthritis Centre
🇨🇦
Windsor, Ontario, Canada
Universitair Medisch Centrum (UMC) Utrecht
🇳🇱
Utrecht, Netherlands
Unidad de Enfermedades Reumaticas y Cronico Degenerativas S. C.
🇲🇽
Torreon, Coahuila, Mexico
Middlemore Hospital Middlemore Clinical Trials Trust
🇳🇿
Auckland, New Zealand
Sarawak General Hospital
🇲🇾
Kuching, Sarawak, Malaysia
Hospital Selayang, Department of Medicine
🇲🇾
Batu Caves, Selangor, Malaysia
Investigacion y Biomedicina de Chihuahua SC
🇲🇽
Chihuahua, Mexico
University of Liverpool Academic Rheumatology Unit. Aintree University Hospital. Liverpool Universit
🇬🇧
Liverpool, United Kingdom
Hospital Regional Universitario de Malaga
🇪🇸
Malaga, Spain
Emmed Research
🇿🇦
Pretoria, Gauteng, South Africa
Unidad de Investigaciones Reumatologicas
🇲🇽
San Luis Potosi, Mexico
Hospital Plato
🇪🇸
Barcelona, Spain
Timaru Hospital
🇳🇿
Timaru, New Zealand
Centro de Investigacion Clinica Trujillo E.I.R.L. Clinica Peruana Americana
🇵🇪
Trujillo, LA Libertad, Peru
Medical Center Leeuwarden
🇳🇱
Leeuwarden, Netherlands
Rheumatology Clinic, Waikato Hospital
🇳🇿
Hamilton, New Zealand
Investigaciones Clinicas S.A.C.
🇵🇪
Lima, Peru
Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy
🇵🇱
Bydgoszcz, Poland
Wellington Hospital
🇳🇿
Wellington, New Zealand
Municipal Budgetary Institution "Central City Clinical Hospital #6"
🇷🇺
Yekaterinburg, Russian Federation
SBEI of HPE Ural State Medical University of the MoH of the RF
🇷🇺
Yekaterinburg, Russian Federation
Rheuma Medicus Zaklad Opieki Zdrowotnej
🇵🇱
Warsaw, Poland
Ponce Medical School Foundation, Inc.
🇵🇷
Ponce, Puerto Rico
Gaziantep Universitesi Tip Fakultesi
🇹🇷
Gaziantep, Turkey
Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj
🇵🇱
Poznan, Poland
Izmir Tepecik Egitim ve Arastirma Hastanesi
🇹🇷
Izmir, Turkey
Ondokuz Mayis Universitesi Tip Fakultesi Fiziksel Tip ve
🇹🇷
Samsun, Turkey
Saint-Petersburg State Budgetary Institution of Healthcare Municipal hospital # 40 of the
🇷🇺
St. Petersburg, St.petersburg, Russian Federation
Hospital Universitario de Basurto
🇪🇸
Bilbao, Vizcaya, Spain
Clinresco Centres ( Pty ) Ltd
🇿🇦
Kempton Park, Gauteng, South Africa
SBHI of Moscow City Clinical Hospital 1 n. a. N.I. Pirogov of the Healthcare Department of Moscow
🇷🇺
Moscow, Russian Federation
ECCLESIA s.r.o, Reumatologicka ambulancia
🇸🇰
Nove Zamky, Slovakia
Consulting and Diagnostic Rheumatological Center Healthy Joints LLC
🇷🇺
Novosibirsk, Russian Federation
Jakaranda Hospital
🇿🇦
Pretoria, Gauteng, South Africa
Tiervlei Trial Centre, Karl Bremer Hospital
🇿🇦
Bellville, Cape Town, Western CAPE, South Africa
Federal State Budgetary Scientific Institution "Research Institute of Fundamental and
🇷🇺
Novosibirsk, Russian Federation
Hospital Universitario de Cruces
🇪🇸
Barakaldo, Vizcaya, Spain
The Royal Wolverhampton NHS Trust-Cannock Chase Hospital
🇬🇧
Cannock, United Kingdom
Adnan Menderes Universitesi Tip Fakultesi Hastanesi
🇹🇷
Aydin, Turkey
Changhua Christian Hospital
🇨🇳
Changhua City, Taiwan
Istanbul Universitesi Cerrahpasa Tip Fakultesi
🇹🇷
Istanbul, Turkey
Hospital De La Santa Creu I Sant Pau
🇪🇸
Barcelona, Spain
Buddhist Dalin Tzu Chi General Hospital
🇨🇳
Chia-Yi, Taiwan
Ankara Universitesi Tip Fakultesi Ibn-i Sina Hastanesi
🇹🇷
Ankara, Turkey
Hacettepe Universitesi Tip Fakultesi
🇹🇷
Ankara, Turkey
Cumhuriyet Universitesi Tip Fakultesi Hastanesi
🇹🇷
Sivas, Turkey
Clinical trials, Pharmacy Department, Aintree University Hospitals
🇬🇧
Liverpool, United Kingdom
Winelands Medical Research Centre-
🇿🇦
Stellenbosch, South Africa
Wits Clinical Research Site
🇿🇦
Johannesburg, Gauteng, South Africa
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
Westroads Clinical Research, Inc.
🇺🇸
Omaha, Nebraska, United States
Arthritis Associates and Osteoporosis Center of Colorado Springs
🇺🇸
Colorado Springs, Colorado, United States
MBAL Sveta Marina EAD
🇧🇬
Varna, Bulgaria
University of Alabama at Birmingham (UAB), Arthritis Clinical Intervention Program
🇺🇸
Birmingham, Alabama, United States
Rheumatology Associates of North Alabama, PC
🇺🇸
Huntsville, Alabama, United States
Southern Arizona VA Health Care System (SAVAHCS)
🇺🇸
Tucson, Arizona, United States
Arthritis And Rheumatism Associates LLC
🇺🇸
Jonesboro, Arkansas, United States
CHI St. Vincent Medical Group Hot Springs
🇺🇸
Hot Springs, Arkansas, United States
University of Arizona Clinical and Translational Science Research Center
🇺🇸
Tucson, Arizona, United States
Medvin Clinical Research
🇺🇸
Whittier, California, United States
Med Investigations, Inc.
🇺🇸
Fair Oaks, California, United States
Valerius Medical Group And Research Center Of Greater Long Beach, Inc.
🇺🇸
Long Beach, California, United States
ProHealth Partners
🇺🇸
Long Beach, California, United States
Keck Medicine of USC
🇺🇸
Los Angeles, California, United States
California Medical Research Associates Inc
🇺🇸
Northridge, California, United States
Dr. Orrin M. Troum, Md And Medical Associates
🇺🇸
Santa Monica, California, United States
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
🇺🇸
Torrance, California, United States
Harbor UCLA Medical Center
🇺🇸
Torrance, California, United States
Desert Valley Medical Group
🇺🇸
Victorville, California, United States
Howard University Hospital
🇺🇸
Washington, District of Columbia, United States
Robin K. Dore M.D., Inc.
🇺🇸
Tustin, California, United States
Florida Clinical Research Group (Administrative Office)
🇺🇸
Clearwater, Florida, United States
Centre for Rheumatology, Immunology and Arthritis
🇺🇸
Fort Lauderdale, Florida, United States
Ocala Rheumatology Research Center
🇺🇸
Ocala, Florida, United States
Arthritis & osteoporosis treatment center,PA
🇺🇸
Orange Park, Florida, United States
Advanced Clinical Research of Orlando
🇺🇸
Ocoee, Florida, United States
Arthritis Center, Inc.
🇺🇸
Palm Harbor, Florida, United States
Advanced Urgent Care
🇺🇸
Port Orange, Florida, United States
Medical Associates of North Georgia - Rheumatology
🇺🇸
Canton, Georgia, United States
USF Health Morsani Center for Advanced Healthcare
🇺🇸
Tampa, Florida, United States
Arthritis Research of Florida, Inc.
🇺🇸
Palm Harbor, Florida, United States
Advanced Medical Research Center
🇺🇸
Port Orange, Florida, United States
Office of Jefrey D. Lieberman, MD, PC
🇺🇸
Decatur, Georgia, United States
Quincy Medical Group
🇺🇸
Quincy, Illinois, United States
Arthritis Treatment Center
🇺🇸
Frederick, Maryland, United States
Klein & Associates, M.D.,P.A.
🇺🇸
Cumberland, Maryland, United States
Klein & Associates, MD, PA
🇺🇸
Hagerstown, Maryland, United States
Phase III Clinical Research
🇺🇸
Fall River, Massachusetts, United States
Bronson Healthcare Group
🇺🇸
Battle Creek, Michigan, United States
Bronson Rheumatology Specialists
🇺🇸
Kalamazoo, Michigan, United States
Jasper Clinic, Inc.
🇺🇸
Kalamazoo, Michigan, United States
Borgess Medical Center
🇺🇸
Kalamazoo, Michigan, United States
Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research
🇺🇸
Kalamazoo, Michigan, United States
June DO,PC
🇺🇸
Lansing, Michigan, United States
Borgess Research Institute
🇺🇸
Kalamazoo, Michigan, United States
St. Paul Rheumatology, PA
🇺🇸
Eagan, Minnesota, United States
Clinvest Research, LLC
🇺🇸
Springfield, Missouri, United States
Physician Research Collaboration, LLC
🇺🇸
Lincoln, Nebraska, United States
Glacier View Research Institute
🇺🇸
Kalispell, Montana, United States
Summit Medical Group
🇺🇸
Clifton, New Jersey, United States
Northwell Health Division of Rheumatology
🇺🇸
Great Neck, New York, United States
Weill Cornell Physicians at Brooklyn Heights
🇺🇸
Brooklyn, New York, United States
NYU Langone Rheumatology Associates Long Island.
🇺🇸
Lake Success, New York, United States
St. Alexius Medical Center
🇺🇸
Bismarck, North Dakota, United States
Frycare outpatient imaging Center
🇺🇸
Hickory, North Carolina, United States
PMG Research of Hickory, LLC
🇺🇸
Hickory, North Carolina, United States
PMG Research Inc., d/b/a PMG Research of Piedmont HealthCare
🇺🇸
Statesville, North Carolina, United States
Physicians East, PA
🇺🇸
Greenville, North Carolina, United States
STAT Research, Inc.
🇺🇸
Dayton, Ohio, United States
Trinity Health Center - Medical Arts
🇺🇸
Minot, North Dakota, United States
The Arthritis Group
🇺🇸
Philadelphia, Pennsylvania, United States
Altoona Center for Clinical Research
🇺🇸
Duncansville, Pennsylvania, United States
Clinical Research Center of Reading, LLC
🇺🇸
Wyomissing, Pennsylvania, United States
Articluaris Healthcare Group d/b/a ACME Research
🇺🇸
Orangeburg, South Carolina, United States
Dr. Ramesh C. Gupta MD, Office of
🇺🇸
Memphis, Tennessee, United States
Trinity Universal Research Associates, Inc
🇺🇸
Carrollton, Texas, United States
Pioneer Research Solutions, Inc.
🇺🇸
Cypress, Texas, United States
Southwest Rheumatology Research, LLC
🇺🇸
Mesquite, Texas, United States
Center for Arthritis and Rheumatic Diseases, P.C.
🇺🇸
Suffolk, Virginia, United States
Rheumatic Disease Center
🇺🇸
Glendale, Wisconsin, United States
OMI- Organizacion Medica de Investigacion
🇦🇷
Buenos Aires, Caba, Argentina
Sanatorio Parque S.A y Consultorios Externos Asociados
🇦🇷
Rosario, Argentina
Consultorios Reumatologicos Pampa.
🇦🇷
Buenos Aires, Argentina
Centro Medico Privado de Reumatologia
🇦🇷
San Miguel de Tucuman, Tucuman, Argentina
CIER - Centro de Investigaciones en Enfermedades Reumaticas
🇦🇷
Caba, Argentina
Hospital Privado Centro Medico de Cordoba S.A.
🇦🇷
Cordoba, Argentina
I.A.R.I. Instituto de Asistencia Reumatologica Integral - Sede IMAC
🇦🇷
San Isidro, Argentina
CER San Juan
🇦🇷
San Juan, Argentina
The Queen Elizabeth Hospital
🇦🇺
Woodville South, South Australia, Australia
CMIP- Centro Mineiro de Pesquisa Ltda/CETAL- Centro de Estudos e Tratamento do Aparelho Locomotor
🇧🇷
Juiz De Fora, MG, Brazil
Hospital de Clinicas de Porto Alegre - UFRGS
🇧🇷
Porto Alegre, RS, Brazil
Instituto de Assistencia Medica do Hospital do Servidor Publico Estadual
🇧🇷
Sao Paulo, SP, Brazil
Clinica Medica Bonfliglioli Ltda.
🇧🇷
Campinas, SP, Brazil
Fundacao Faculdade de Medicina MECMPAS - Hospital das Clinicas da FMUSP
🇧🇷
Sao Paulo, SP, Brazil
Hospital Israelita Albert Einstein
🇧🇷
Sao Paulo, SP, Brazil
Hospital Moinhos de Vento
🇧🇷
Rio Grande De Sul, Brazil
CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda
🇧🇷
Sao Paulo, Brazil
Centro Medico de Reumatologia Ltda.
🇨🇱
Temuco, Region DE LA Araucania, Chile
Centre de Recherche Musculo-Squelettique
🇨🇦
Trois-Rivieres, Quebec, Canada
Centro de Investigacion Clinica Universidad Catolica (CICUC)
🇨🇱
Santiago, Region Metropolitana, Chile
Prosalud
🇨🇱
Santiago, Metropolitana, Chile
Guangdong General Hospital
🇨🇳
Guangzhou, Guangdong, China
Centro Integral de Reumatologia REUMALAB S.A.S.
🇨🇴
Medellin, Antioquia, Colombia
Centro de Investigaciones Clinica del Country
🇨🇴
Bogota, Cundinamarca, Colombia
Mediscan Group, s.r.o.
🇨🇿
Praha 11, Czech Republic, Czechia
Revmacentrum MUDr. Mostera, s.r.o.
🇨🇿
Brno - Zidenice, Czechia
Helsingin yliopistollinen keskussairaala
🇫🇮
Helsinki, Finland
Revmatologicky ustav.
🇨🇿
Praha 2, Czechia
Revmatologicka Ambulance
🇨🇿
Praha 4, Czechia
PV - MEDICAL s.r.o.
🇨🇿
Zlin, Czechia
Kiljavan Laaketutkimus Oy
🇫🇮
Hyvinkaa, Finland
Barzilai Medical Center - Rheumatology Outpatient Clinic
🇮🇱
Ashkelon, Israel
Assaf Harofeh Medical Center
🇮🇱
Beer Yaacov, Israel
Carmel Medical Center
🇮🇱
Haifa, Israel
Rambam Health Care Campus
🇮🇱
Haifa, Israel
Centro de Investigacion de Reumatologia - Clinica San Borja
🇵🇪
Lima, Peru
Indywidualna Praktyka lekarska Dr hab. med. Anna Szczepańska - Szerej
🇵🇱
Lublin, Poland
Zespol Poradni Specjalistycznych Reumed Filia Onyksowa
🇵🇱
Lublin, Poland
PROFMEDICUS Sp. z o.o., Osrodek Badan Klinicznych
🇵🇱
Olsztyn, Poland
Centrum Medyczne Pratia Warszawa
🇵🇱
Warszawa, Poland
SBHI City Clinical Hospital #4 of HD of Moscow
🇷🇺
Moscow, Russian Federation
Fundacion de Investigaction de Diego
🇵🇷
San Juan, Puerto Rico
ROMJAN s.r. o. , Specializovana Reumatologicka ambulancia
🇸🇰
Bratislava - Petrzalka, Slovakia
Saint-Petersburg State Budget Healthcare Institution Consultative-diagnostic Center #85
🇷🇺
St. Petersburg, Russian Federation
REUMACENTRUM s.r.o., Reumatologicka ambulancia
🇸🇰
Partizanske, Slovakia
Federal State Budgetary Educational Institution of Higher Education
🇷🇺
Smolensk, Russian Federation
Arthritis Clinical Research Trials cc
🇿🇦
Cape Town, Western CAPE, South Africa
Panorama Medical Centre
🇿🇦
Cape Town, Western CAPE, South Africa
Hospital Universitario 12 de Octubre
🇪🇸
Madrid, Spain
Hospital Nuestra Senora de la Esperanza
🇪🇸
Santiago de Compostela, LA Coruna, Spain
Hospital Universitario Virgen de la Macarena
🇪🇸
Sevilla, Spain
National Cheng Kung University Hospital
🇨🇳
Tainan, Taiwan
Aintree University Hospital, Liverpool University Hospitals
🇬🇧
Liverpool, United Kingdom
Kocaeli Universitesi Tip Fakultesi Hastanesi
🇹🇷
Kocaeli, Turkey
Barking, Havering and Redbridge University Hospitals NHS Trust
🇬🇧
Goodmayes, Essex, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Clinical Research Facility
🇬🇧
Newcastle Upon Tyne, United Kingdom
International Medical Research
🇺🇸
Daytona Beach, Florida, United States
Dr.Robert W. Levin MDOffice of
🇺🇸
Clearwater, Florida, United States
Ventura Clinical Trials
🇺🇸
Ventura, California, United States
University of California, San Diego (UCSD)- Perlman Ambulatory Clinic
🇺🇸
La Jolla, California, United States
Bay Area Arthritis and Osteoporosis
🇺🇸
Brandon, Florida, United States
University of Florida College of Medicine, Jacksonville - Rheumatology Research
🇺🇸
Jacksonville, Florida, United States
Talbert Medical Group
🇺🇸
Huntington Beach, California, United States
Center for Diagnostic Imaging
🇺🇸
Mendota Heights, Minnesota, United States
Arthritis & Rheumatism Associates (Private Practice)
🇺🇸
Clearwater, Florida, United States
University of Florida - Rheumatology at ACC
🇺🇸
Jacksonville, Florida, United States
UMass Memorial Medical Center, Memorial Campus
🇺🇸
Worcester, Massachusetts, United States
Millennium Research
🇺🇸
Ormond Beach, Florida, United States
San Marcus Research Clinic
🇺🇸
Miami Lakes, Florida, United States
Arthritis and Diabetes Clinic, Inc.
🇺🇸
Monroe, Louisiana, United States
Springfield Clinic
🇺🇸
Springfield, Illinois, United States
PMG Research of Hickory LLC
🇺🇸
Hickory, North Carolina, United States
University of Nevada School of Medicine
🇺🇸
Las Vegas, Nevada, United States
Shores Rheumatology P.C.
🇺🇸
Saint Clair Shores, Michigan, United States
Arthritis Center Of Reno
🇺🇸
Reno, Nevada, United States
Nashua Rheumatology
🇺🇸
Nashua, New Hampshire, United States
Arthritis Centers of Texas
🇺🇸
Dallas, Texas, United States
Carolina Arthritis Associates
🇺🇸
Wilmington, North Carolina, United States
UPMC Lupus Center of Excellence
🇺🇸
Pittsburgh, Pennsylvania, United States
Innovative Clinical Research, LLC
🇺🇸
Greenville, South Carolina, United States
St. Vincent's Hospital (Melbourne)
🇦🇺
Fitzroy, Victoria, Australia
Piedmont Arthritis Clinic, PA
🇺🇸
Greenville, South Carolina, United States
Amarillo Center for Clinical Research, Ltd.
🇺🇸
Amarillo, Texas, United States
Vesalion, s.r.o.
🇨🇿
Ostrava, Czech Republic, Czechia
Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology
🇺🇸
Summerville, South Carolina, United States
Rheumatology Consultants, PLLC
🇺🇸
Knoxville, Tennessee, United States
West Tennessee Research Institute
🇺🇸
Jackson, Tennessee, United States
CPCLin - Centro de Pesquisas Clinicas Ltda. / Clinica Dr. Freddy Goldberg Eliaschewitz LTDA EPP
🇧🇷
Sao Paulo, SP, Brazil
Trinity Universal Research Associates, Inc.
🇺🇸
Plano, Texas, United States
Accurate Clinical Research, Inc.
🇺🇸
League City, Texas, United States
CCBR Brasil - Centro de Pesquisas e Analises Clinicas LTDA
🇧🇷
Rio de Janeiro, RJ, Brazil
Arthritis and Osteoporosis Associates, LLP
🇺🇸
Lubbock, Texas, United States
Servimed S.A.S
🇨🇴
Bucaramanga, Santander, Colombia
Center for Arthritis and Rheumatic Diseases, PC
🇺🇸
Chesapeake, Virginia, United States
AACD- Lar Escola\ Associacao de Assistencia a Crianca Deficiente
🇧🇷
Sao Paulo, SP, Brazil
Austin Health - Repatriation Hospital
🇦🇺
Heidelberg West, Victoria, Australia
GBUZ RK Republic Hospital n. a. V.A. Baranov of the MoH & social development Of The Karelia Republic
🇷🇺
Petrozavodsk, Russian Federation
Bnai Zion Medical Center Rheumatology Unit
🇮🇱
Haifa, Israel
SBIH of Nizhniy Novgorod region City Clinical Hospital #5 of Nizhniy Novgorod district
🇷🇺
Nizhniy Novgorod, Russian Federation
St. Augustine's Hospital - Chelmsford Medical Centre 2
🇿🇦
Durban, Kwa-zulu Natal, South Africa
MBAL Eurohospital Plovdiv OOD
🇧🇬
Plovdiv, Bulgaria
Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S
🇨🇴
Bogota D.C., Cundinamarca, Colombia
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
🇲🇽
Mexico, Distrito Federal, Mexico
Centrum Medyczne Pratia Katowice
🇵🇱
Katowice, Poland
Pomorskie Centrum Reumatologiczne im. Dr Jadwigi Titz-Kosko w Sopocie, Spolka. z o.o.
🇵🇱
Sopot, Poland
Synexus Polska Sp. z o.o.
🇵🇱
Wroclaw, Poland
Nestatna reumatologicka ambulancia
🇸🇰
Bratislava, Slovakia
Chung Shan Medical University Hospital
🇨🇳
Taichung City, Taiwan
Ramathibodi Hospital, Mahidol University
🇹🇭
Bangkok, Thailand
The University of Hong Kong (HKU)-Queen Mary Hospital (QMH)
🇭🇰
Hong Kong, Hong Kong
Prince of Wales Hospital
🇭🇰
Shatin, Hong Kong
Consultorio de Reumatologia
🇲🇽
Mexico, Distrito Federal, Mexico
ABK REUMA S.R.L. de Medicentro Biociencias- BIO CIENCIAS PERU S.R.L.
🇵🇪
Lima, Peru
NZOZ Lecznica MAK-MED
🇵🇱
Nadarzyn, Mazowieckie, Poland
Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
🇵🇱
Bialystok, Podlaskie, Poland
NZOZ Biogenes Sp. z o.o.
🇵🇱
Wroclaw, Poland
Reuma-Global s.r.o., Reumatologicka ambulancia
🇸🇰
Trnava, Slovakia
China Medical University Hospital
🇨🇳
Taichung City, Taiwan (r.o.c), Taiwan
Hospital Raja Permaisuri Bainun
🇲🇾
Ipoh, Perak, Malaysia
Preventive Care S.A.S.
🇨🇴
Chia, Cundinamarca, Colombia
King Abdullah University Hospital
🇯🇴
Irbid, Jordan
Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC
🇲🇽
Morelia, Michoacan, Mexico
Unidad Reumatologica Las Americas S.C.P.
🇲🇽
Merida, Yucatan, Mexico
CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C.
🇲🇽
Ciudad de Mexico, Mexico
Centro de lnvestigacion de la Red Asistencial del Hospital Nacional ESSALUD Carlos Alberto Seguin E.
🇵🇪
Arequipa, Peru
KO-MED Centra Kliniczne Sp. zo.o.
🇵🇱
Staszow, Poland
Chang Gung Medical Foundation - Linkou Branch
🇨🇳
Taoyuan City, Taiwan
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽
Guadalajara, Jalisco, Mexico
Greenacres Hospital
🇿🇦
Port Elizabeth, Eastern CAPE, South Africa
MBAL RUSe AD,
🇧🇬
Ruse, Bulgaria
UMBAL Sveti Ivan Rilski" EAD
🇧🇬
Sofia, Bulgaria
Centro Integral en Reumatologia SA de CV
🇲🇽
Guadalajara, Jalisco, Mexico
Laakarikeskus Aava Hyvinkaan Pipetti
🇫🇮
Hyvinkaa, Finland
Istishari Hospital
🇯🇴
Amman, Jordan
Centro de Investigacion Clinica de Morelia. S.C
🇲🇽
Morelia, Michoacan, Mexico
Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.
🇲🇽
San Luis Potosi, Mexico
ACQ MEDIC S.A.C. - Centro de Investigacion Clinica Inmunoreumatologia
🇵🇪
Lima, Peru
Unidad de Investigacion de la Clinica Internacional - Clinica Internacional
🇵🇪
Lima, Peru
Instituto Peruano del Hueso y la Articulacion - Instituto Peruano del Hueso y la Articulacion S.A.C.
🇵🇪
Lima, Peru
Investigaciones en Reumatologia - Centro Medico Corpac
🇵🇪
Lima, Peru
Synexus Polska Sp. z o.o. Oddzial w Gdyni
🇵🇱
Gdynia, Poland
NASZ LEKARZ Przychodnie Medyczne
🇵🇱
Torun, Poland
Reumex s.r.o
🇸🇰
Rimavska Sobota, Slovakia
Hospital de Merida
🇪🇸
Merida, Badajoz, Spain
Faculty of Medicine , Siriraj Hospital , Mahidol University
🇹🇭
Bangkok, Thailand
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine,Chiang Mai University
🇹🇭
Chiang Mai, Thailand
Prince of Songkla University
🇹🇭
Songkhla, Thailand
University of Cape Town
🇿🇦
Cape Town, Western CAPE, South Africa
Phramongkutklao Hospital
🇹🇭
Bangkok, Thailand
Taipei Veterans General Hospital
🇨🇳
Taipei, Taiwan
Poole Hospital, University Hospitals Dorset NHS Foundation Trust
🇬🇧
Poole, Dorset, United Kingdom
Rheumatology Associates of Central Florida, PA
🇺🇸
Orlando, Florida, United States
Omega Research Consultants, LLC
🇺🇸
Orlando, Florida, United States
Kansas City Internal Medicine
🇺🇸
Kansas City, Missouri, United States
Rheumatology Associates, P.A.
🇺🇸
Charleston, South Carolina, United States
Austin Regional Clinic
🇺🇸
Austin, Texas, United States
Rheumatology Research Associates
🇨🇦
Edmonton, Alberta, Canada
Hospital Universitario Marques de Valdecilla
🇪🇸
Santander, Cantabria, Spain
Northumbria Healthcare NHS Foundation Trust
🇬🇧
North Shields, United Kingdom
Pamela Youde Nethersole Eastern Hospital
🇭🇰
Chai Wan, HKG, Hong Kong
Tuen Mun Hospital
🇭🇰
Hong Kong, Hong Kong